(CURE) Direxion Daily Healthcare - Overview
ETF Category: Trading--Leveraged Equity | Exchange: NYSE ARCA (USA) | Market Cap: 158m USD | Total Return: 34.9% in 12m
Avg Turnover: 6.93M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The Direxion Daily Healthcare Bull 3X Shares (CURE) seeks daily investment results, before fees and expenses, of 300% of the performance of the Health Care Select Sector Index. The fund allocates at least 80% of its net assets to financial instruments, including swap agreements and futures contracts, to achieve this leveraged exposure. Its holdings focus on domestic companies within pharmaceuticals, biotechnology, healthcare technology, and medical equipment providers.
The healthcare sector is traditionally considered defensive due to inelastic demand for medical services, though the integration of biotechnology and life sciences tools introduces higher R&D costs and regulatory volatility. Because this ETF resets daily, it is designed for short-term tactical trading rather than long-term investment, as compounding can lead to significant deviations from the index over time. You may find it useful to examine how these leverage mechanics align with your strategy on ValueRay. As a non-diversified fund, CURE maintains concentrated positions that may result in higher price fluctuations compared to broad market benchmarks.
- Daily healthcare index performance volatility amplifies leveraged gains and losses
- Pharmaceutical drug pricing legislation impacts sector-wide revenue projections
- Federal Reserve interest rate shifts influence biotech venture capital funding
- Medicare reimbursement policy changes affect healthcare provider profit margins
- FDA approval cycles drive significant price movement in biotechnology holdings
As of May 29, 2026, the stock is trading at USD 97.35 with a total of 121,399 shares traded.
Over the past week, the price has changed by +7.47%,
over one month by +13.73%,
over three months by -18.92% and
over the past year by +34.94%.
Direxion Daily Healthcare has no consensus analysts rating.